MTST (MetaStat) Cash And Cash Equivalents : $0.32 Mil (As of Feb. 2018)

View and export this data going back to 2008. Start your Free Trial

What is MetaStat Cash And Cash Equivalents?

MetaStat's quarterly cash and cash equivalents declined from Aug. 2017 ($1.73 Mil) to Nov. 2017 ($0.78 Mil) but then stayed the same from Nov. 2017 ($0.78 Mil) to Feb. 2018 ($0.32 Mil).

MetaStat's annual cash and cash equivalents increased from Feb. 2016 ($0.36 Mil) to Feb. 2017 ($0.78 Mil) but then declined from Feb. 2017 ($0.78 Mil) to Feb. 2018 ($0.32 Mil).

MetaStat Cash And Cash Equivalents Historical Data

The historical data trend for MetaStat's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MetaStat Cash And Cash Equivalents Chart

MetaStat Annual Data

Trend

Feb09

Feb10

Feb11

Feb12

Feb13

Feb14

Feb15

Feb16

Feb17

Feb18

Cash And Cash Equivalents

Get a 7-Day Free Trial

0.48

0.26

0.36

0.78

0.32

MetaStat Quarterly Data
	May13	Aug13	Nov13	Feb14	May14	Aug14	Nov14	Feb15	May15	Aug15	Nov15	Feb16	May16	Aug16	Nov16	Feb17	May17	Aug17	Nov17	Feb18
Cash And Cash Equivalents	Get a 7-Day Free Trial															0.78	0.15	1.73	0.78	0.32

MetaStat Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

MetaStat (OTCPK:MTST) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

MetaStat Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of MetaStat's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

MetaStat Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MetaStat Inc (OTCPK:MTST) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

27 Drydock Avenue, 2nd Floor, Boston, MA, USA, 02210

Website

http://www.metastat.com

MetaStat Inc is a US-based biotechnology company which focuses on discovering and developing personalized therapeutic (Rx) and diagnostic (Dx) treatment solutions for cancer patients. The company focuses on development programs of the novel therapeutic product candidates that target the Mena protein isoform whereas the Companion Diagnostics program is focused on developing companion tests to be used in combination with cancer drugs, that provide essential information for the safe and effective use of a corresponding drug or biological product to improve patient outcome. It also develops a prognostic diagnostic program which is focused on developing diagnostic tests that predict the risk of future metastasis in cancer patients following the initial treatment of their primary tumor.

Executives

Daniel H Schneiderman	officer: VP OF FINANCE AND SECRETARY	760 PARKSIDE AVE. SUITE 304, SUITE 207, BROOKLYN NY 11226
Jerome B Zeldis	director	8767 E. VIA DE VENTURA, SUITE 190, SCOTTSDALE AZ 85258
Paul Billings	director	11055 FLINTKOTE AVENUE, SUITE B, SAN DIEGO CA 92121
Richard J Berman	director	305 COLLEGE ROAD EAST, PRINCETON NJ 08540
Martin J Driscoll	director	C/O JAVELIN PHARMACEUTICALS, INC., 125 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140
Oscar Bronsther	director	4 AUTUMNWOOD COURT, THE WOODLANDS TX 77380
Johan M. Spoor	director	500 BOYLSTON STREET, SUITE 1600, BOSTON MA 02116
David N Siegel	director	T-S CAPITAL PARTNERS, LLC, 1350 TREAT BOULEVARD, SUITE 400, WALNUT CREEK CA 94597
Warren C Lau	director	2635 N. CRESCENT RIDGE DRIVE, THE WOODLANDS TX 77381
Patrick T Mooney	director	C/O SONTRA MEDICAL CORPORATION, 10 FORGE PARKWAY, FRANKLIN MA 02038
David M. Epstein	director	OSI PHARMACEUTICALS, INC., 41 PINELAWN ROAD, MELVILLE NY 11747
Richard W Perkins	10 percent owner	730 EAST LAKE STREET, WAYZATA MN 55391
Harvey Judkowitz	director	10220 SW 124 ST, MIAMI FL 33176

MetaStat Headlines

No Headlines